Company profile
Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Relutrigine | phase2_3 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07010471 | phase3 | active_not_recruiting | 2025-07-09 | 2026-12-01 | Praxis Precision Medicines | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine |
| NCT05021991 | phase2 | completed | 2021-10-14 | 2023-02-09 | Praxis Precision Medicines | A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor |
| NCT04969510 | phase2 | completed | 2021-06-24 | 2022-07-15 | Praxis Precision Medicines | A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder |
| NCT07019922 | phase3 | recruiting | 2025-08-13 | 2026-12-01 | Praxis Precision Medicines | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety |
| NCT05387642 | phase2 | withdrawn | 2022-04-05 | 2022-06-30 | Praxis Precision Medicines | A Clinical Trial of PRAX-114 in Participants With Essential Tremor |
FDA applications (0)
No records yet.